Longeveron Inc is a biotechnology company focused on developing cellular therapies to address age-related and life-threatening conditions
The company specializes in the research and commercialization of innovative treatments, particularly those utilizing mesenchymal stem cells derived from umbilical cord tissue. Longeveron aims to improve the quality of life for patients suffering from diseases such as Alzheimer’s and cardiac dysfunction by harnessing the potential of these advanced therapies to promote regeneration and improve overall health outcomes. Through its commitment to scientific research and clinical trials, Longeveron is at the forefront of modern medicine, exploring new avenues for healing and enhancing longevity.
Longeveron (NASDAQLGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, will be represented at the upcoming UBS Virtual Organ Restoration and Cell Therapy Day. According to the announcement, Longeveron CEO Wa’el Hashad will be participating in a fireside chat during the Oct. 15, 2024, virtual event. During the fireside chat, Hashad will be talking with Ash Verma, SMID-cap biotech and specialty pharma analyst for UBS Equity Research Ash Verma. The event is slated to begin at 3 p.m. ET.
Longeveron (NASDAQLGVN) is a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions. The company today announced that it will attend the Cell & Gene Meeting on the Mesa, organized by the Alliance for Regenerative Medicine . The conference is scheduled for October 7-9, 2024, in Phoenix, Arizona.
Longeveron (NASDAQLGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced a positive Type C meeting with the U.S. Food and Drug Administration (“FDA”). The meeting supported the advancement of Lomecel-B(TM) , a proprietary, scalable, allogeneic, investigational cellular therapy currently being evaluated in a Phase 2b clinical trial (“ELPIS II”) for hypoplastic left heart syndrome (“HLHS”) . According to the announcement, Longeveron and the FDA reached foundational alignment on ELPIS II primary and secondary endpoints as well as on the need to submit the company’s prespecified Statistical Analysis Plan (“SAP”) and Chemistry, Manufacturing and Controls (“CMC”) readiness plan, including Lomecel-B(TM) stability and comparability data, for prior review.
Longeveron (NASDAQLGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, will be spotlighted at next month’s H.C. Wainwright 26th Annual Global Investment Conference; the event is scheduled for Sept. 9–11, 2024. According to the announcement, company officials are slated to present on Sept. 10 at 5 p.m. ET. Following the conference, an archived replay of the webcast will be available on the Longeveron website.
Longeveron (NASDAQLGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced that it will present a late breaking poster at the 17th edition of the Clinical Trials on Alzheimer’s Disease Conference (“CTAD24”). The poster is titled “Lomecel-B inhibition of MMP14 activity predicts Lomecel-B bioactivity in the treatment of mild Alzheimer’s disease.” The conference is taking place in Madrid, Spain, from October 29, 2024, to November 1, 2024.
Longeveron (NASDAQLGVN), a clinical-stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, will be presenting at the 51st meeting of the Congenital Heart Surgeons’ Society. The meeting is scheduled for Oct. 27–28, 2024, in Chicago. Longeveron’s presentation will be part of the event’s Scientific Session II. Titled “Long-Term Transplant-Free Survival Is Improved in Hypoplastic Left Heart Syndrome with Cell-Based Therapy,” the presentation is slated to begin at 3:10 p.m. ET on Oct. 27.
Longeveron (NASDAQLGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, is reporting on its second-quarter 2024 financial results, as well as key business milestones. Highlights of the report include positive data from LGNV’s phase 2a clinical trial designed to evaluate Lomecel-B(TM) in Alzheimer’s disease being presented at the Alzheimer’s Association International Conference(R) (“AAIC”); receiving both Regenerative Medicine Advanced Therapy (“RMAT”) designation and Fast Track designation for Lomecel-B from the U.S. Food and Drug Administration (“FDA”); reaching 70% enrollment in phase 2b clinical trial evaluating Lomecel-B in rare pediatric disease Hypoplastic Left Heart Syndrome (“HLHS”); and financing transaction and warrant exercises raising $15.3 million in gross proceeds, which will be used to fund continued clinical development.
Longeveron (NASDAQLGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, is planning to release its second-quarter 2024 financial report after markets close on Aug. 14, 2024. The company also announced that it has scheduled a conference call and webcast on the same day to discuss the report and provide a company update; the call will begin at 4:30 p.m. ET. To access the call, dial 1.877-407-0789 and then use the conference ID 13747923. An archived replay of the webcast will be available on company website following the event.
A look at the most-searched tickers on Benzinga Pro for the month of July shows some familiar names like Tesla, Nvidia and Apple. Here's a look at the others.
Longeveron presented promising Phase 2a clinical trial data for Lomecel-B at the AAIC 2024. The trial showed the drug's safety and efficacy in treating Alzheimer's, demonstrating slowed disease progression, improved daily living activities, and minimized brain volume loss.
Longeveron (NASDAQLGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, is presenting results from its Clear Mind phase 2a clinical trial at the Alzheimer’s Association International Conference(R) (“AAIC”). The conference began on July 28, 2024, and runs through Aug. 1, 2024; the event is being held in person in Philadelphia as well as online. According to the announcement, a Featured Research Session oral presentation discussed findings that show Longeveron’s Lomecel-B improved cognitive function, quality of life and brain volume in the treatment of mild Alzheimer’s disease. The company also noted that the study met key objectives, including advancing data supporting favorable benefit/risk profile, supporting target engagement and providing additional support for the efficacy profile of Lomecel-B. In addition, Lomecel-B minimized the loss in brain volume in areas associated with Alzheimer’s disease. “As a medicinal signaling cell therapy that has multiple potential mechanisms of action to address inflammatory responses in the brain, Lomecel-B offers potential to address the underlying pathology of Alzheimer’s disease without the limitations of previous therapies,” said Longeveron CEO Wa’el Hashad in the press release. “We are very encouraged by the safety profile and efficacy evidence that support the differentiated therapeutic potential of Lomecel-B and lay the foundation for its future clinical development. We’re pleased to connect with the Alzheimer’s community at AAIC 2024 and contribute to the growing body of evidence that fuels the continued development of novel therapeutics for this devastating disease.”
